Satoshi Ito

Senior Director, Japan Section Head, Global AD Commercial and Patient Journey, Global AD Office at Eisai Co., Ltd.

Speaker

Satoshi is an associate director in Project Management Office of Global AD Office in Eisai Co.,Ltd. He is working as a project manager for lecanemab and other AD portfolio focusing on global medical and diagnostics functions as well as collaboration network function. He joined Eisai Co., Ltd. In 2007 and was involved in a lot of clinical developments especially for dementia portfolio including donepezil hydrochloride, lemborexant, elenbecestat, lecanemab and E2814 until moving to diagnostics side. He has been collaborating with several diagnostic companies to support their assay development as an IVD since 2020. He worked in Eisai Inc. in the US to align with the internal global marketing and medical teams and accelerate diagnostic development from 2021 to 2023. After that, moving back to Japan, he worked in open innovation to scout cutting-edge technologies and innovative assets and introduce into the company in order to accelerate and expand the company R&D. Before joining Eisai, he had developed amyloid and tau PET probes at Tohoku University.